A Phase 2 interventional study of Adalimumab, current formulation and Adalimumab, new formulation in Rheumatoid Arthritis, sponsored by AbbVie (prior sponsor, Abbott). Completed at 21 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-06-11.
Sponsored by AbbVie (prior sponsor, Abbott) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies in Arthritis, Rheumatoid by AbbVie — 5 open to participants now, 6 under way, 1 of them phase 3. Arthritis, Rheumatoid · AbbVie.
Among the 80 studies in Arthritis, Rheumatoid by AbbVie, this one is the 24th largest by enrollment of the 38 interventional ones that give a count, is one of 8 that started in 2012, is one of 16 in phase 2, and was the 29th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →5 of the 80 studies in Arthritis, Rheumatoid by AbbVie are open now, in 12 countries. Recruiting first, the newest first:
AbbVie · Sites in United States, Japan
Ages 18–75
AbbVie · Sites in United States, Canada, Czechia and 9 more countries
Ages 18+
Capstan Therapeutics · Sites in Australia
Ages 18–65 · Healthy volunteers
AbbVie · Sites in Germany
Ages 18+
AbbVie
Ages 18+
By country, each count listing its studies:
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 17 · Phase 3 12 · Phase 4 4
First in 2000; this study’s year is marked. 8 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is close to the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 210 across the 38 interventional studies, 401 across the 41 observational. Of the 71 that completed or were terminated, 54 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under AbbVie (prior sponsor, Abbott), one of the names counted as AbbVie. Under that name alone:
AbbVie (prior sponsor, Abbott) is the lead sponsor of 223 studies on the registry; none are open to participants now.
2 of the studies in Arthritis, Rheumatoid by AbbVie that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06972446AbbVieA Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis | 2027-02 |
| NCT06917742Capstan TherapeuticsA Study of Intravenous CPTX2309 in Healthy Participants and Participants With Moderate to Severe Rheumatoid Arthritis (RA) or Systemic Lupus Erythematosus (SLE) | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 80 studies in Arthritis, Rheumatoid by AbbVie, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A study in Rheumatoid Arthritis (RA) patients to evaluate two formulations of adalimumab for pharmacodynamics, pharmacokinetics, and safety.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
New formulation adalimumab 40 mg every other week
Biological: Adalimumab, new formulation
Current formulation adalimumab 40 mg every other week
Biological: Adalimumab, current formulation
Current formulation adalimumab 40 mg every other week
Also known as: Humira
New formulation adalimumab 40 mg every other week
Serum Concentrations of Adalimumab at Weeks 12 and 24
Blood samples for adalimumab analysis were collected by venipuncture and serum concentrations of adalimumab were determined using a validated enzyme-linked immunoadsorbent assay (ELISA) method.
Time frame: Measured at Weeks 12 and 24
Mean Disease Activity Scores (DAS28) at Weeks 12 and 24
The Disease Activity Score (DAS28) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C-reactive protein, and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score \>5.1 indicates high disease activity, a DAS28 score \<3.2 indicates low disease activity, and a DAS28 score \<2.6 indicates clinical remission.
Time frame: Measured at Weeks 12 and 24
Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Weeks 12 and 24
American College of Rheumatology 20% (ACR20) response. A participant is a responder if the following 3 criteria for improvement from baseline are met: * ≥ 20% improvement in tender joint count; * ≥ 20% improvement in swollen joint count; and * ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Disability Index of the Health Assessment Questionnaire * CRP (Acute phase reactant (Erythrocyte sedimentation rate/C-reactive protein))
Time frame: Measured at Weeks 12 and 24
Percentage of Participants With an American College of Rheumatology (ACR) 50 Response at Weeks 12 and 24
American College of Rheumatology 50% (ACR50) response. A participant is a responder if the following 3 criteria for improvement from baseline are met: * ≥ 50% improvement in tender joint count; * ≥ 50% improvement in swollen joint count; and * ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Disability Index of the Health Assessment Questionnaire * CRP (Acute phase reactant (Erythrocyte sedimentation rate/C-reactive protein))
Time frame: Measured at Weeks 12 and 24
Mean Health Assessment Questionnaire (HAQ-DI) Scores at Weeks 12 and 24
The Health Assessment Questionnaire - Disability Index (HAQ-DI) is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. The minimal clinically important difference (MCID) defined for the HAQ-DI is ≥0.22. HAQ remission indicating normal physical function is defined by HAQ-DI \< 0.5.
Time frame: Measured at Weeks 12 and 24
Mean Short Form-36 (SF-36) Physical Component Summary Scores and Mental Component Summary Scores at Weeks 12 and 24
The Short Form 36 (SF-36) determines participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 primarily contribute to the physical component summary score (PCS) of the SF-36. Items 5-8 primarily contribute to the mental component summary score (MCS) of the SF-36. Scores on each item are summed and averaged (range = 0 (maximum disability) - 100 (no disability). The standard recall period is four weeks.
Time frame: Measured at Weeks 12 and 24
Percentage of Participants Positive for Anti-adalimumab Antibody
Percentage of participants with anti-adalimumab antibody
Time frame: Measured through Week 24
Number of Participants With Adverse Events
An adverse event was defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which did not necessarily have a causal relationship with the treatment. See the Reported Adverse Events Section for more details.
Time frame: From time of informed consent to 70 days following the last dose of study drug
Mean Injection Site Pain on a Visual Analogue Scale (VAS)
The Visual Analogue Scale (VAS) consisted of a horizontal 100 mm line, with 0 representing "no pain" and 100 representing "worst possible pain". Participants placed a mark on the line representing their current level of pain immediately after injections on Day 1 of the study.
Time frame: Immediately after injections on Day 1
| Milestone | New Formulation of Adalimumab 40 mg Every Other Week | Current Formulation Adalimumab 40 mg Every Other Week |
|---|---|---|
| Started | 50 | 50 |
| Completed | 49 | 47 |
| Not completed | 1 | 3 |
| Withdrew: Withdrew consent due to an adverse event | 1 | 1 |
| Withdrew: Serious adverse event/withdrew consent | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
Blood samples for adalimumab analysis were collected by venipuncture and serum concentrations of adalimumab were determined using a validated enzyme-linked immunoadsorbent assay (ELISA) method.
| µg/mL | New Formulation of Adalimumab 40 mg Every Other Week | Current Formulation Adalimumab 40 mg Every Other Week |
|---|---|---|
| Week 12: n= 46 (new), n=43 (current) | 5.72 ± 4.49 | 6.23 ± 4.29 |
| Week 24: n= 47 (new), n=41 (current) | 5.95 ± 5.13 | 6.17 ± 4.50 |
The Disease Activity Score (DAS28) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C-reactive protein, and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score \>5.1 indicates high disease activity, a DAS28 score \<3.2 indicates low disease activity, and a DAS28 score \<2.6 indicates clinical remission.
| units on a scale | New Formulation of Adalimumab 40 mg Every Other Week | Current Formulation Adalimumab 40 mg Every Other Week |
|---|---|---|
| Week 12 | 3.78 ± 0.147 | 3.82 ± 0.148 |
| Week 24 | 3.54 ± 0.152 | 3.46 ± 0.153 |
American College of Rheumatology 20% (ACR20) response. A participant is a responder if the following 3 criteria for improvement from baseline are met: * ≥ 20% improvement in tender joint count; * ≥ 20% improvement in swollen joint count; and * ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Disability Index of the Health Assessment Questionnaire * CRP (Acute phase reactant (Erythrocyte sedimentation rate/C-reactive protein))
| percentage of participants | New Formulation of Adalimumab 40 mg Every Other Week | Current Formulation Adalimumab 40 mg Every Other Week |
|---|---|---|
| Week 12 | 62.0 | 68.0 |
| Week 24 | 68.0 | 68.0 |
American College of Rheumatology 50% (ACR50) response. A participant is a responder if the following 3 criteria for improvement from baseline are met: * ≥ 50% improvement in tender joint count; * ≥ 50% improvement in swollen joint count; and * ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Disability Index of the Health Assessment Questionnaire * CRP (Acute phase reactant (Erythrocyte sedimentation rate/C-reactive protein))
| percentage of participants | New Formulation of Adalimumab 40 mg Every Other Week | Current Formulation Adalimumab 40 mg Every Other Week |
|---|---|---|
| Week 12 | 36.0 | 40.0 |
| Week 24 | 48.0 | 50.0 |
The Health Assessment Questionnaire - Disability Index (HAQ-DI) is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. The minimal clinically important difference (MCID) defined for the HAQ-DI is ≥0.22. HAQ remission indicating normal physical function is defined by HAQ-DI \< 0.5.
| units on a scale | New Formulation of Adalimumab 40 mg Every Other Week | Current Formulation Adalimumab 40 mg Every Other Week |
|---|---|---|
| Week 12 | 1.10 ± 0.075 | 1.02 ± 0.076 |
| Week 24 | 1.01 ± 0.082 | 0.97 ± 0.083 |
The Short Form 36 (SF-36) determines participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 primarily contribute to the physical component summary score (PCS) of the SF-36. Items 5-8 primarily contribute to the mental component summary score (MCS) of the SF-36. Scores on each item are summed and averaged (range = 0 (maximum disability) - 100 (no disability). The standard recall period is four weeks.
| units on a scale | New Formulation of Adalimumab 40 mg Every Other Week | Current Formulation Adalimumab 40 mg Every Other Week |
|---|---|---|
| PCS score- Week 12 | 38.88 ± 0.957 | 39.08 ± 0.974 |
| PCS score- Week 24 | 39.38 ± 1.044 | 39.94 ± 1.022 |
| MCS score- Week 12 | 44.78 ± 1.172 | 42.78 ± 1.192 |
| MCS score- Week 24 | 43.16 ± 1.246 | 45.46 ± 1.267 |
Percentage of participants with anti-adalimumab antibody
| Percentage of participants | New Formulation of Adalimumab 40 mg Every Other Week | Current Formulation Adalimumab 40 mg Every Other Week |
|---|---|---|
| Percentage of Participants Positive for Anti-adalimumab Antibody | 14 | 16 |
An adverse event was defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which did not necessarily have a causal relationship with the treatment. See the Reported Adverse Events Section for more details.
| participants | New Formulation of Adalimumab 40 mg Every Other Week | Current Formulation Adalimumab 40 mg Every Other Week |
|---|---|---|
| Number of Participants With Adverse Events | 31 | 34 |
The Visual Analogue Scale (VAS) consisted of a horizontal 100 mm line, with 0 representing "no pain" and 100 representing "worst possible pain". Participants placed a mark on the line representing their current level of pain immediately after injections on Day 1 of the study.
| Millimeters | New Formulation of Adalimumab 40 mg Every Other Week | Current Formulation Adalimumab 40 mg Every Other Week |
|---|---|---|
| Mean Injection Site Pain on a Visual Analogue Scale (VAS) | 14.4 ± 22.6 | 35.9 ± 29.2 |
Collected over Adverse events were collected from the time of study drug administration until 70 days following the last dose. Serious adverse events were collected from the time the participant signed the informed consent.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| New Formulation of Adalimumab 40 mg Every Other Week | — | 0/50 (0%) | 23/50 (46%) |
| Current Formulation Adalimumab 40 mg Every Other Week | — | 2/50 (4%) | 16/50 (32%) |
| Event | New Formulation of Adalimumab 40 mg Every Other Week | Current Formulation Adalimumab 40 mg Every Other Week |
|---|---|---|
| THORACIC VERTEBRAL FRACTUREInjury, poisoning and procedural complications | 0/50 | 1/50 |
| TRANSITIONAL CELL CARCINOMANeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/50 | 1/50 |
| Event | New Formulation of Adalimumab 40 mg Every Other Week | Current Formulation Adalimumab 40 mg Every Other Week |
|---|---|---|
| NASOPHARYNGITISInfections and infestations | 5/50 | 6/50 |
| NAUSEAGastrointestinal disorders | 4/50 | 0/50 |
| CYSTITISInfections and infestations | 4/50 | 2/50 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 4/50 | 4/50 |
| RHEUMATOID ARTHRITISMusculoskeletal and connective tissue disorders | 3/50 | 4/50 |
| DYSPEPSIAGastrointestinal disorders | 3/50 | 1/50 |
| INJECTION SITE REACTIONGeneral disorders | 3/50 | 0/50 |
| SINUSITISInfections and infestations | 3/50 | 1/50 |
| COUGHRespiratory, thoracic and mediastinal disorders | 3/50 | 1/50 |
| Age, Continuous(years) | New Formulation of Adalimumab 40 mg Every Other Week | Current Formulation Adalimumab 40 mg Every Other Week | Total |
|---|---|---|---|
| Mean | 55.5 ± 11.0 | 53.0 ± 12.3 | 54.3 ± 11.6 |
| Sex: Female, Male(Participants) | New Formulation of Adalimumab 40 mg Every Other Week | Current Formulation Adalimumab 40 mg Every Other Week | Total |
|---|---|---|---|
| Female | 41 | 41 | 82 |
| Male | 9 | 9 | 18 |
The record gives a start of Jun 2012, a primary completion of May 2013 and a completion of May 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2014, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AbbVie (prior sponsor, Abbott) →